Juvenile Toxicity Study

Juvenile Toxicity Study describes nonclinical safety studies conducted in immature animals to assess potential effects of a drug on developing organ systems. These studies support paediatric development programmes by identifying risks related to growth, neurodevelopment, immune function, and reproductive maturation. Juvenile studies are designed based on intended paediatric population, dosing duration, and mechanism of action.

The biopharmaceutical industry performs juvenile toxicity studies when paediatric exposure is anticipated and adult studies may not adequately predict developmental risk. Study design includes selecting appropriate species, dosing windows aligned with human development stages, and endpoints assessing organ development. Regulatory agencies evaluate juvenile study necessity on a case-by-case basis, with paediatric investigation plans and paediatric study requirements guiding development obligations. Results inform paediatric trial design, dose selection, and risk mitigation strategies. As paediatric drug development expands through regulatory incentives and ethical obligations to include children in clinical research, juvenile toxicity studies remain important safety tools ensuring appropriate characterisation of developmental risks.